Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Communication Via EHRs Will Improve Rx Adherence, Despite Lack Of HHS Standard, Official Says

Executive Summary

Although a specific criterion directly measuring medication adherence is not part of the meaningful use standard for electronic health records, they offer tools to help ensure patients take their medications.

You may also be interested in...



PhRMA Wants Medication Adherence Coalition To Address Communication Restrictions

At the Council for Affordable Health Coverage’s event to launch its Prescription for Healthy America campaign, PhRMA President and CEO John Castellani says opening up the ability of drug manufacturers to communicate about their products could help improve medication adherence.

CBO Legislative Scores Will Account For Medicare Rx’s Reductions In Other Medical Costs

In a policy change, the Congressional Budget Office, which estimates the impact of legislation on federal spending, will account for pharmaceuticals’ effect on overall medical spending in Medicare for bills that directly affect drug use.

Drug Non-Adherence Costs Manufacturers Billions Of Dollars In Revenues – Study

Capgemini’s calculations of potential pharmaceutical revenues if patients were fully compliant with their drug therapy regimens suggest revenues in the U.S. would be nearly 60% higher. But even small changes have sizeable revenue impact.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS054971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel